# Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

> **NCT01077154** · PHASE3 · TERMINATED · sponsor: **Amgen** · enrollment: 4509 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT01077154
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06-02
- **Primary completion:** 2017-08-31
- **Final completion:** 2018-03-26
- **Target enrollment:** 4509 (ACTUAL)
- **Why stopped:** Terminated: Amgen decision following Primary Analysis. Not due to safety reason
- **Last updated:** 2021-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01077154

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01077154, "Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01077154. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*